SecBot SecBot
PRESS-RELEASE ·Filed May 28, 2026

COGT

Cogent Biosciences, Inc.
BULLISH
Impact 8/10
Horizonmonths Processed5mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

NDA acceptance with Priority Review and no AdCom is a strong positive signal. The PDUFA date of Nov 30, 2026 provides a clear catalyst. ASCO presentation on May 30 may drive near-term volatility.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$35.38
T+0 close · May 28, 2026 · via day close
Latest settled
+3.82%
T+60 · $36.73
Vs SPY
+2.08%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 28 $35.38entry
  2. T+1 · 6mo ago −1.19%α −1.43% · $34.96
  3. T+5 · 6mo ago −8.82%α −8.77% · $32.26
  4. T+20 · 5mo ago +7.69%α +10.83% · $38.10
  5. T+60 · 3mo ago +3.82%α +2.08% · $36.73
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Cogent Biosciences announced FDA acceptance of its NDA for bezuclastinib in combination with sunitinib for GIST, with Priority Review and a PDUFA date of November 30, 2026. The Phase 3 PEAK trial showed a median PFS of 16.5 months vs 9.2 months (HR=0.50, p<0.0001) and a 46% ORR vs 26% for sunitinib alone. This is a major regulatory milestone for a first-in-class combination that could transform second-line GIST treatment, with no advisory committee planned and no identified review issues.

Key Facts

  • FDA accepted NDA for bezuclastinib + sunitinib in GIST with Priority Review; PDUFA date November 30, 2026
  • Phase 3 PEAK trial: median PFS 16.5 months (combination) vs 9.2 months (sunitinib alone); HR=0.50 (95% CI: 0.39-0.65, p<0.0001)
  • ORR 46% for combination vs 26% for sunitinib monotherapy in imatinib-resistant patients
  • No advisory committee planned; FDA communicated no potential review issues identified
  • Full PEAK results to be presented at ASCO oral session on May 30, 2026
  • Company preparing for launches in both GIST and systemic mastocytosis later this year
  • Expanded Access Programs established for U.S. patients with GIST or SM

Financial Impact

First approval for a novel KIT inhibitor combination in GIST; potential peak sales in the hundreds of millions to billions given GIST prevalence and clear superiority over standard of care

revenuemarket cappipeline value

Risk Factors

  • FDA could issue a Complete Response Letter at PDUFA despite current positive signals
  • Hepatic safety signals (ALT/AST elevations) could become a review focus
  • Commercial launch execution risk in both GIST and SM
  • Overall survival data remains immature; negative OS readout could limit label expansion

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
84% bullish (19 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3302753

Track record

13 reports on COGT

Performance horizon

4 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +17.43% at T+20 after the Jun 12, 2026 report. 4 of 5 went positive at some point.

Filters
  1. Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $33.54 Now $27.44 −18.19% settles Feb 5
  2. Nov 5, 202611d ago 8-K Neutral 4/10 No price data
  3. Nov 5, 202611d ago Press Release Neutral 5/10 Entry $31.65 Now $27.44 −13.29% settles Feb 4
  4. Aug 10, 202614w ago 8-K Neutral 5/10 No price data
  5. Aug 10, 202614w ago Press Release Neutral 5/10 Entry $41.53 to $31.06 Now $27.44 −33.93% ▼ −25.21% −22.79% vs SPY
  6. Aug 9, 202614w ago Institutional Cluster Bullish 6/10 Entry $41.53 to $31.06 Now $27.44 −33.93% ▼ −25.21% −22.79% vs SPY
  7. Jun 12, 202622w ago Press Release Neutral 4/10 Entry $33.10 to $35.28 Now $27.44 −17.10% ▲ +6.59% +3.32% vs SPY
  8. Jun 12, 202622w ago Press Release Bullish 7/10 Entry $33.10 to $35.28 Now $27.44 −17.10% ▲ +6.59% +3.32% vs SPY
  9. May 30, 202624w ago Press Release Bullish 8/10 Entry $34.81 to $36.80 Now $27.44 −21.17% ▲ +5.72% +4.49% vs SPY
  10. May 28, 202624w ago Press Release Bullish 8/10 Viewing Entry $35.38 to $36.73 Now $27.44 −22.44% ▲ +3.82% +2.08% vs SPY
Showing 10 of 13

US Market Status

Market Closed · Opens in 6h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 28, 2026